AntriaBio

Financials

Investors

Financials

v3.10.0.1
Consolidated Balance Sheets - USD ($)
Sep. 30, 2018
Jun. 30, 2018
Current assets    
Cash $ 400,871 $ 1,645,872
Other current assets 372,114 361,915
Total current assets 772,985 2,007,787
Non-current assets    
Fixed assets, net 178,719 368,374
Intangible assets, net 35,207 37,030
Deferred lease asset 25,439 32,850
Deposits 56,841 56,841
Total non-current assets 296,206 495,095
Total Assets 1,069,191 2,502,882
Current liabilities:    
Accounts payable and accrued expenses 1,788,387 1,706,154
Accrued payroll 868,565 770,976
Convertible notes payable, net 4,137,232 3,434,611
Embedded derivative liability 55,000 73,904
Deferred lease liability, current portion 132,922 113,997
Interest payable 356,996 148,372
Total current liabilities 7,339,102 6,248,014
Non-current liabilities:    
Deferred lease liability, less current portion 148,224 190,577
Deposit liability 25,046 25,046
Total non-current liabilities 173,270 215,623
Total Liabilities 7,512,372 6,463,637
Commitments and Contingencies (Note 10)
Stockholders' (deficit) equity:    
Preferred stock, $0.001 par value; 20,000,000 shares authorized; none issued and outstanding 0 0
Common stock, $0.001 par value, 200,000,000 shares authorized; 62,166,309 shares issued and outstanding, September 30, 2018 and June 30, 2018 62,168 62,168
Additional paid-in capital 91,043,622 90,160,815
Accumulated deficit (97,548,971) (94,183,738)
Total stockholders' deficit (6,443,181) (3,960,755)
Total Liabilities and Stockholders' Deficit $ 1,069,191 $ 2,502,882
v3.10.0.1
Consolidated Statements of Operations - USD ($)
3 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Research and development    
Compensation and benefits $ 557,391 $ 1,500,864
Consultants and outside costs 46,705 130,361
Material manufacturing costs 72,932 426,089
Facilities and other costs 249,698 502,657
Total research and development 929,909 4,310,637
General and administrative    
Compensation and benefits 1,249,696 1,795,427
Professional fees 121,923 223,594
Investor relations 44,013 59,871
General and administrative 239,340 327,600
Loss (Gain) on sale of fixed assets (22,852) 0
Total General and Administrative 1,632,120 2,406,492
Total operating expenses 2,562,029 6,717,129
Loss from operations (2,562,029) (6,717,129)
Other income (expense)    
Interest income 28 337
Rent income 89,466 31,838
Interest expense (911,602) 0
Derivative gains 18,904 342
Total other income (803,204) 32,517
Net loss (3,365,233) (6,684,612)
Net loss attributable to common stock $ (3,365,233) $ (6,684,612)
Net loss per common share - basic and diluted $ (0.05) $ (0.13)
Weighted average number of common shares outstanding - basic and diluted 62,166,309 52,887,981
Clinical trial costs    
Research and development    
Cost of Goods and Services Sold $ 3,184 $ 979,766
License costs    
Research and development    
Cost of Goods and Services Sold $ 0 $ 770,900
v3.10.0.1
Consolidated Statements of Cash Flows - USD ($)
3 Months Ended
Sep. 30, 2018
Sep. 30, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (3,365,233) $ (6,684,612)
Amortization of intangible asset 1,823 1,823
Amortization of debt discount and debt issuance costs 702,621
Depreciation expense 25,368 266,613
Gain on sale of fixed assets (22,852) 0
Stock-based compensation expense 877,951 1,507,699
Derivative gains (18,904) (342)
Warrant expense 4,856 14,847
Changes in operating assets and liabilities:    
(Increase) decrease in other current assets (10,199) 92,845
Decrease in deferred lease asset 7,411 5,731
Increase (decrease) in accounts payable and accrued expenses 179,822 (84,636)
Increase in interest payable 208,624 0
Decrease in deferred lease liability (23,428) (24,975)
Net Cash Used In Operating Activities (1,432,140) (4,905,007)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of fixed assets 0 (5,816)
Proceeds from sale of equipment 187,139 0
Return of security deposit 0 0
Net Cash Provided By (Used) In Investing Activities 187,139 (5,816)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Payments on lease payable 0 0
Proceeds from issuance of equity financing 0 4,500,000
Payment of placement agent compensation and issuance costs 0 (60,000)
Net Cash Provided by Financing Activities 0 4,440,000
Net decrease in cash (1,245,001) (470,823)
Cash - Beginning of Period 1,645,872 4,486,538
Cash - End of Period 400,871 4,015,715
Cash Paid During the Period for:    
Taxes 0 0
Interest $ 0 $ 0